Interact with experts and peers.

Recent Posts

10 of 17 Shown
  • My Take: Addressing Patient Reluctance to Switch From an Originator to Its Biosimilar for Treatment of Rheumatic Disease

    Jonathan Kay MD - 2/13/2018
    Despite demonstration of comparable efficacy and safety between biosimilars and their originators, some patients avoid this treatment switch. Here’s my take on steps to assuage unfounded patient fears.
  • My Take: Navigating Biosimilars for IBD

    Russell D. Cohen MD, FACG, AGAF - 12/6/2017 2 comments / Last Comment: 1/26/2018
    As biosimilars penetrate the GI treatment space, here’s my take on what gastroenterologists need to know.
  • Answers to Your Patients’ Questions About Biosimilars in Rheumatology

    Beth L. Jonas MD - 7/18/2017 1 comment / Last Comment: 7/24/2017
    What should you tell your rheumatology patients about biosimilars?
  • The End of Winter or a False Spring? Introduction of Biosimilars in a Rheumatology Practice

    William F. C. Rigby MD - 6/12/2017 1 comment / Last Comment: 7/12/2017
    What does the availability of biosimilar products mean in your approach to rheumatologic conditions?
  • Key Considerations for Using Biosimilars in IBD

    David T. Rubin MD - 6/6/2017 1 comment / Last Comment: 6/22/2017
    The role of biosimilars in the setting of IBD is growing. Here’s my take on some of the key things you need to consider when using these agents.
  • Biosimilars: Addressing Uncertainties With a New Drug Class

    Kenneth G. Saag MD, MSc - 3/13/2017 3 comments / Last Comment: 12/15/2017
    Biosimilars promise increased access and decreased prices for patients in need of expensive biologics. However, as with any new category of drug, biosimilars face some uncertainties. Here’s my take.
  • Targeting IL-17 in Psoriatic Arthritis: Key Data From the 2016 ACR Meeting

    Arthur Kavanaugh MD - 2/1/2017 2 comments / Last Comment: 2/13/2018
    The 2016 American College of Rheumatology annual meeting gave us promising data on agents targeting IL-17 in psoriatic arthritis. Here’s my take on select abstracts.
  • JAK Inhibitors in Rheumatoid Arthritis: Weighing the Anticipated Options

    Roy Fleischmann MD - 9/9/2016 1 comment / Last Comment: 12/15/2016
    Clinical trial data to date have shown tofacitinib and baricitinib to be largely similar in efficacy and safety. But are there meaningful differences that might help clinicians choose between them? Here’s my take.
  • My Take on New ASAS/EULAR Recommendations for Managing Axial Spondyloarthritis

    Atul Deodhar MD - 7/22/2016
    I describe noteworthy differences between the newly updated ASAS/EULAR recommendations and the ACR/SAA/SPARTAN recommendations.
  • New Developments in Ankylosing Spondylitis from EULAR 2016

    Atul Deodhar MD - 7/15/2016 1 comment / Last Comment: 8/13/2016
    Dr. Atul Deodhar reviews new insights into the pathogenesis of AS and clinical trial updates that may affect your practice.
10 of 17 Shown
Show 7 More